Oct 03, 2018
On Tuesday, October 9, 2018, at 11 AM, EDT, Deciphera Pharmaceuticals hosted a webinar for the Systemic Mastocytosis (SM) community about Living with Systemic Mastocytosis, and Deciphera Pharmaceuticals’ ongoing clinical trial of DCC-2618, an investigational drug being testing in people with smoldering and advanced forms of Systemic Mastocytosis.
Oliver Rosen, MD, Chief Medical Officer at Deciphera Pharmaceuticals, and Kathy Gram, RN, Head of Patient Advocacy, presented an overview of Deciphera Pharmaceuticals and information about living with SM, as well as previously published data on DCC-2618 and some information about the ongoing clinical trial.
Once a video of the presentation is posted online, it will be available for 30 days at the following link: https://www.deciphera.com/patients/patient-resources/
For questions, please email firstname.lastname@example.org.
Deciphera Pharmaceuticals is in Phase 1 of its ongoing expansion clinical trial of treatment with DCC-2618. DCC-2618 is a kinase switch control inhibitor being tested as a potential treatment for gastrointestinal stromal tumors (GISTs), systemic mastocytosis (SM), gliomas, and other solid tumors driven by KIT kinase or PDGFRα kinase.
Deciphera Pharmaceuticals’ goal is to focus on the development of DCC-2618 in patient subgroups where there is a significant unmet medical need.
Approximately 94% of SM patients are reported to have a somatic D816V mutation in KIT. This D816V mutation is a gain-of-function mutation in the KIT activation switch, which leads to unregulated KIT activation. The KIT receptor, which is widely expressed on mast cells, stimulates signaling pathways that control cell growth, differentiation, and survival. The D816V gain-of-function mutation enables mast cells to proliferate in the absence of normal activation signals.
Patients who are interested in exploring participation in the ongoing Phase 1 expansion clinical trial can learn more at clinicaltrials.gov or by emailing Jama Pitman at email@example.com for a referral to a participating trial site.
Deciphera Pharmaceuticals would like to thank everyone involved in the development and execution of the ongoing Phase 1 Expansion clinical trial, including patients, families, medical investigators, and clinical staff who have all held an important role in the clinical trial.
DCC-2618 is an investigational drug and has not been approved by any regulatory authority.